Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease (INTRUST1)

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00846586
First received: February 15, 2009
Last updated: July 22, 2011
Last verified: July 2011
  Purpose

This study assessed the efficacy and safety of indacaterol (150 µg once daily [od]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease (COPD)


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Indacaterol 150 μg
Drug: Tiotropium 18 μg
Drug: Placebo to indacaterol
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Controlled, Parallel-group, 12-week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 µg Once Daily With Open Label Tiotropium 18 µg Once Daily Versus Open Label Tiotropium 18 µg Once Daily in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose at the End of Treatment (Week 12) [ Time Frame: From 5 minutes to 8 hours post-dose at the end of treatment (Week 12, Day 84) ] [ Designated as safety issue: No ]
    FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5 and 30 minutes; and 1, 2, 3, 4, 6, and 8 hours post-dose at the end of the study (Week 12, Day 84). Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.


Secondary Outcome Measures:
  • Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of Treatment (Week 12 + 1 Day, Day 85) [ Time Frame: 24 hours post-dose at the end of treatment (Week 12 + 1 day, Day 85) ] [ Designated as safety issue: No ]
    FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of the study (Week 12 + 1 day, Day 85). The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.

  • Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose on Day 1 [ Time Frame: From 5 minutes to 8 hours post-dose on Day 1 ] [ Designated as safety issue: No ]
    FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5 and 30 minutes; and 1, 2, 3, 4, 6, and 8 hours post-dose on Day 1. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.

  • Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose on Day 2 [ Time Frame: 24 hours post-dose on Day 2 ] [ Designated as safety issue: No ]
    FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 23 hours 10 minutes and 23 hours 45 minutes post-dose on Day 2. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.

  • Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose on Day 1 [ Time Frame: From 5 minutes to 4 hours post-dose on Day 1 ] [ Designated as safety issue: No ]
    FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5 and 30 minutes; and 1, 2, 3, and 4 hours post-dose on Day 1. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.

  • Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose at the End of Treatment (Week 12) [ Time Frame: From 5 minutes to 4 hours post-dose at the end of treatment (Week 12) ] [ Designated as safety issue: No ]
    FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5 and 30 minutes; and 1, 2, 3, and 4 hours post-dose at the end of treatment (Week 12). Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.


Enrollment: 1134
Study Start Date: March 2009
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Indacaterol 150 μg and tiotropium 18 μg
Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
Drug: Indacaterol 150 μg
Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Drug: Tiotropium 18 μg
Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).
Active Comparator: Tiotropium 18 μg
Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
Drug: Tiotropium 18 μg
Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).
Drug: Placebo to indacaterol
Placebo to indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease [GOLD] Guidelines, 2007) and:

    1. Smoking history of at least 10 pack-years
    2. Post-bronchodilator forced expiratory volume in 1 second (FEV1) ≤ 65% and ≥ 30% of the predicted normal value
    3. Post-bronchodilator FEV1/FVC (force vital capacity) < 70%

Exclusion Criteria:

  • Patients who have had a COPD exacerbation requiring systemic glucocorticosteroid treatment or antibiotics and/or hospitalization in the 6 weeks prior to screening or during the run-in period
  • Patients who have had a respiratory tract infection within 6 weeks prior to screening or during the run-in period
  • Patients with a body mass index less than 15 or more than 40 kg/m^2
  • Patients with concomitant pulmonary disease
  • Patients with a history of asthma
  • Patients with diabetes Type I or uncontrolled diabetes Type II
  • Any patient with lung cancer or a history of lung cancer
  • Patients with a history of certain cardiovascular comorbid conditions

Other protocol-defined inclusion/exclusion criteria applied to the study.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00846586

  Hide Study Locations
Locations
United States, Alabama
Novartis Investigator Site
Birmingham, Alabama, United States, 32509
Novartis Investigator Site
Mobile, Alabama, United States, 36608
United States, Arizona
Novartis Investigative Site
Scottsdale, Arizona, United States, 85258
Novartis Investigative Site
Tucson, Arizona, United States, 85712
Novartis Investigative Site
Tucson, Arizona, United States, 85723
United States, Arkansas
Novartis Investigator Site
Pine Bluff, Arkansas, United States, 71603
United States, California
Novartis Investigator Site
Fountain Valley, California, United States, 92708
Novartis Investigator Site
Long Beach, California, United States, 90822
Novartis Investigative Site
Los Angeles, California, United States, 90095
Novartis Investigator Site
National City, California, United States, 91950
Novartis Investigator Site
Palmdale, California, United States, 93551
Novartis Investigative Site
Stockton, California, United States, 95207
Novartis Investigator Site
Temecula, California, United States, 92591
United States, Connecticut
Novartis Investigative Site
Hartford, Connecticut, United States, 06105-1208
United States, Florida
Novartis Investigative Site
Clearwater, Florida, United States, 33756
Novartis Investigator Site
Ft. Walton Beach, Florida, United States, 32547
Novartis Investigative Site
Miami, Florida, United States, 33136
Novartis Investigative Site
Miami, Florida, United States, 331577
Novartis Investigative Site
Naranja, Florida, United States, 33032
Novartis Investigator Site
Pensacola, Florida, United States, 32514
Novartis Investigator Site
Sarasota, Florida, United States, 34233
United States, Georgia
Novartis Investigative Site
Atlanta, Georgia, United States, 30342
Novartis Investigator Site
Conyers, Georgia, United States, 30094
United States, Illinois
Novartis Investigative Site
Normal, Illinois, United States, 61761
United States, Iowa
Novartis Investigative Site
Iowa City, Iowa, United States, 52240
United States, Kansas
Novartis Investigative Site
Kansas City, Kansas, United States, 66160
Novartis Investigative Site
Lenexa, Kansas, United States, 66215
Novartis Investigative Site
Topeka, Kansas, United States, 66606
United States, Louisiana
Novartis Investigator Site
Lafayette, Louisiana, United States, 70503
Novartis Investigator Site
Metaire, Louisiana, United States, 70002
Novartis Investigator Site
New Orleans, Louisiana, United States, 70119
Novartis Investigator Site
Slidell, Louisiana, United States, 70458
United States, Maryland
Novartis Investigator Site
Columbia, Maryland, United States, 21044
United States, Massachusetts
Novartis Investigator Site
Brockton, Massachusetts, United States, 02301
United States, Michigan
Novartis Investigator Site
Clarkston, Michigan, United States, 48346
Novartis Investigator Site
Detroit, Michigan, United States, 48202
United States, Missouri
Novartis Investigative Site
St Charles, Missouri, United States, 63301
United States, Montana
Novartis Investigator Site
Missoula, Montana, United States, 59808
United States, Nebraska
Novartis Investigator Site
Boys Town, Nebraska, United States, 68010
Novartis Investigative site
Omaha, Nebraska, United States, 68134
Novartis Investigative Site
Omaha, Nebraska, United States, 68114
United States, Nevada
Novartis Investigative Site
Las Vegas, Nevada, United States, 89119
United States, New Hampshire
Novartis Investigator Site
Lebanon, New Hampshire, United States, 03756
United States, New Jersey
Novartis Investigator Site
Asbury Park, New Jersey, United States, 07712
United States, New York
Novartis Investigative Site
Rochester, New York, United States, 14618
United States, North Carolina
Novartis Investigator Site
Mooresville, North Carolina, United States, 28117
Novartis Investigative Site
Winston-Salem, North Carolina, United States, 27103
United States, Oklahoma
Novartis Investigator Site
Tulsa, Oklahoma, United States, 74135-2920
United States, Oregon
Novartis Investigative Site
Medford, Oregon, United States, 97504
United States, Pennsylvania
Novartis Investigator Site
Bethlehem, Pennsylvania, United States, 18020
United States, Rhode Island
Novartis Investigative Site
Cumberland, Rhode Island, United States, 02864
United States, South Carolina
Novartis Investigator Site
Greenville, South Carolina, United States, 29615
Novartis Investigative Site
Spartanburg, South Carolina, United States, 29303
United States, Tennessee
Novartis Investigator Site
Knoxville, Tennessee, United States, 37919
United States, Texas
Novartis Investigator Site
El Paso, Texas, United States, 79903
Novartis Investigative Site
Houston, Texas, United States, 77024
Novartis Investigative Site
Houston, Texas, United States, 77079
Novartis Investigative Center
New Braunfels, Texas, United States, 78130-6113
United States, Virginia
Novartis Investigator Site
Newport News, Virginia, United States, 23606
Novartis Investigator Site
Richmond, Virginia, United States, 23249
Novartis Investigative Site
Richmond, Virginia, United States, 23225
Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Cordoba, Argentina
Novartis Investigative Site
Corrientes, Argentina
Novartis Investigative SIte
Mendoza, Argentina
Novartis Investigative Site
Rosario, Argentina
Australia
Novartis Investigator Site
Box Hill, Australia
Novartis Investigator Site
Clayton, Australia
Novartis Investigator Site
Garran, Australia
Novartis Investigator Site
Glebe, Australia
Novartis Investigator Site
Kogarah, Australia
Novartis Investigator Site
Nedlands, Australia
Colombia
Novartis Investigative Site
Barranquilla, Colombia
Novartis Investigator Site
Bogota, Colombia
Novartis Investigative Site
Bogota, Colombia
Novartis Investigative Site
Medellin, Colombia
Denmark
Novartis Investigator Site
Copenhagen, Denmark
Novartis Investigator Site
Fredericia, Denmark
Novartis Investigator Site
Silkeborg, Denmark
Novartis Investigator Site
Soeborg, Denmark
Novartis Investigator Site
Vejle, Denmark
Germany
Novartis Investigator Site
Berlin, Germany
Novartis Investigator Site
Cottbus, Germany
Novartis Investigator Site
Donaustauf, Germany
Novartis Investigator Site
Dortmund, Germany
Novartis Investigator Site
Erfurt, Germany
Novartis Investigator Site
Frankfurt, Germany
Novartis Investigator Site
Gelnhausen, Germany
Novartis Investigator Site
Grosshansdorf, Germany
Novartis Investigator Site
Hannover, Germany
Novartis Investigator Site
Heidelberg, Germany
Novartis Investigator Site
Leipzig, Germany
Novartis Investigator Site
Mainz, Germany
Novartis Investigator Site
Neu-Ulm, Germany
Novartis Investigator Site
Neuss, Germany
Novartis Investigator Site
Potsdam, Germany
Novartis Investigator Site
Rostock, Germany
Novartis Investigator Site
Schwabach, Germany
Novartis Investigator Site
Schwetzingen, Germany
Novartis Investigator Site
Straussberg, Germany
Novartis Investigative Site
Wiesbaden, Germany
Novartis Investigator Site
Wuppertal, Germany
Guatemala
Novartis Investigative Site
Guatemala, Guatemala
Novartis Investigative Site
Guatemala City, Guatemala
Mexico
Novartis Investigative Site
Guadalajara, Mexico
Novartis Investigator Site
Mexico City, Mexico
Novartis Investigative Site
Monterrey, Mexico
Novartis Investigative Site
Zapopan, Mexico
Philippines
Novartis Investigator Site
Manila, Philippines
South Africa
Novartis Investigator Site
Amanzimtoti, South Africa
Novartis Investigator Site
Cape Town, South Africa
Novartis Investigator Site
Johannesburg, South Africa
Novartis Investigator Site
Midrand, South Africa
Novartis Investigator Site
Umkomaas, South Africa
Spain
Novartis Investigative Site
Alicante, Spain
Novartis Investigator Site
Barcelona, Spain
Novartis Investigator Site
Begonte, Spain
Novartis Investigator Site
Cadiz, Spain
Novartis Investigator Site
Granollers, Spain
Novartis Investigative Site
Jaén, Spain
Novartis Investigator Site
La Coruna, Spain
Novartis Investigator Site
Leon, Spain
Novartis Investigator Site
Madrid, Spain
Novartis Investigator Site
Pamplona, Spain
Novartis Investigator Site
Torrelavega, Spain
Novartis Investigator Site
Valencia, Spain
Novartis Investigator Site
Vigo, Spain
Turkey
Novartis Investigator Site
Antalya, Turkey
Novartis Investigator Site
Canakkale, Turkey
Novartis Investigator Site
Isparta, Turkey
Novartis Investigator Site
Istanbul, Turkey
Novartis Investigator Site
Kartal, Turkey
Novartis Investigator Site
Kayseri, Turkey
Novartis Investigator Site
Kozlu / Zonguldak, Turkey
Novartis Investigator Site
Malatya, Turkey
Novartis Investigator Site
Manisa, Turkey
Novartis Investigator Site
Mecidiyekoy/Istanbul, Turkey
Novartis Investigator Site
Yenisehir/Izmir, Turkey
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided by Novartis

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: External Affairs, Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00846586     History of Changes
Other Study ID Numbers: CQAB149B2341
Study First Received: February 15, 2009
Results First Received: July 22, 2011
Last Updated: July 22, 2011
Health Authority: United States: Food and Drug Administration
Denmark: Danish Medicines Agency
Spain: Spanish Agency of Medicines
Turkey: Ministry of Health
Australia: Department of Health and Ageing Therapeutic Goods Administration
South Africa: Medicines Control Council
Philippines: Bureau of Food and Drugs
Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Guatemala: Comisión para la Evaluación de Ensayos Clínicos Ministerio de Salud Pública y Asistencia Social
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica

Keywords provided by Novartis:
chronic obstructive pulmonary disease
COPD
indacaterol
tiotropium
bronchodilation

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Tiotropium
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Parasympatholytics
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 18, 2014